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Abstract 
Rodent kidneys exhibit three isoforms of metallothioneins (MTs), MT1, MT2 and MT3, with poorly 
characterized localization along the nephron. Here we studied in adult male Wistar rats the renal 
expression of MTs mRNA by end-point RT-PCR and MT proteins by immunochemical methods. The 
expression pattern of MT1 mRNA was cortex (CO)>outer stripe (OS)=inner stripe (IS)=inner medulla 
(IM), of MT2 mRNA was IM>CO>IS=OS, and of MT3 mRNA was IM>CO=OS=IM. MT1/2-antibody 
stained with heterogeneous intensity the cell cytoplasm and nuclei in proximal tubule (PT) and thin 
ascending limb, whereas MT3-antibody stained weakly the cell cytoplasm in various cortical tubules 
and strongly the nuclei in all nephron segments. However, the isolated nuclei exhibited an absence of 
MT1/2 and presence of MT3 protein. In MT1/2-positive PT cells, the intracellular staining appeared 
diffuse or bipolar, but the isolated brush-border, basolateral and endosomal membranes were devoid of 
MT1/2 proteins. In the lumen of some PT profiles, the heterogeneously sized MT1/2-rich vesicles were 
observed, with the limiting membrane positive for NHE3, but negative for V-ATPase, CAIV, and 
megalin, whereas their interior was positive for CAII and negative for cytoskeleton. They seem to be 
pinched off from the luminal membrane of MT1/2-rich cells, as also indicated by transmission electron 
microscopy. We conclude that in male rats, MTs are heterogeneously abundant in the cell cytoplasm 
and/or nuclei along the nephron. The MT1/2-rich vesicles in the tubule lumen may represent a source 
of urine MT and membranous material, whereas MT3 in nuclei may handle zink and locally-produced 
reactive oxygen species. 
 
Key words:  immunocytochemistry, rat kidney, mRNA expression, proximal tubule, 
transmission electron microscopy, Western blotting 
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1. Introduction 
Metallothioneins (MTs) are small (Mr = 6-8 kDa) cysteine rich proteins which bind Zn, Cd, and a 
few other toxic metals with variable affinity. In adult mammals, functional MTs exist in four isoforms. 
MT1 and MT2 (MT1/2) are widely expressed in different organs and in heterogeneous abundance [1],  
MT3 is found largely in brain, but also in a few other organs [2-6], whereas MT4 is found in some 
stratified squamous epithelia [7]. 
The exact functions of individual MTs have not been resolved. The expression of MT1/2, but not 
of MT3 and MT4, in the liver and other mammalian organs can be induced by a variety of stimuli, 
including some trace metals (Cd, Hg, Zn, Ag, Pt), glucocorticoids, physical stress, inflammation, 
starvation, irradiation, chemicals that produce oxidative radicals, etc. [8-24]. From these studies 
various roles for MT1/2 have been proposed, such as intracellular storage and homeostatic control of 
essential metals (Zn, Cu), absorption and/or excretion of some essential and toxic metals, detoxication 
of toxic metals by sequestration, scavenging of free radicals, protection against alkylating agents, and 
resistance to and/or protection from anticancer drugs. Other studies indicated poorly-defined roles of 
MT1/2 and MT3 in regulation of mitochondrial energy metabolism in mammalian organs, protection 
from DNA damage and apoptosis, regulation of gene expression during certain stages of the cell cycle, 
cell proliferation and differentiation, organs development, transepithelial ion and water transport, 
cancerogenesis and cancer diagnostics, and pathogenesis of some neurodegenerative diseases 
[5,6,16,24-30]. MT3 has also been studied as a growth inhibitory factor (GIF) for neurons and glia in 
human brain [29,31].    
In the mammalian kidneys, besides in homeostatic regulation of essential metals, MTs may play a 
protective role in nephrotoxicity induced by Cd and other toxic metals [11,16,32,33]. In adult rats, by 
biochemical and immunochemical methods a limited abundance of MT1/2 proteins was found largely 
in cortical proximal tubules [10,16,34-40], whereas the MT3 protein was detected in some glomerular 
and collecting duct cells [6]. In the human kidney, MT3 was demonstrated in the cytoplasm of 
epithelial cells in glomeruli, cortical proximal and distal tubules, and collecting ducts [4]. 
An independent, detailed immunolocalization of various MTs along the mammalian nephron has 
not been performed. A recent observation in MT3-transfected cell line of the human proximal tubule, 
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which exhibited formation of domes (not present in non-transfected cells), indicated that MT3 may be 
involved in the renal ion and water transport functions [5,41]. The MT3-transfected cells were also 
more sensitive to Cd-induced cytotoxicity [27,28]. These observations emphasized a need for a detailed 
characterization of MTs expression in various cell types along the mammalian nephron. In addition, a 
limited amount of MT1/2 has been detected in human and animal urine, but its origin has not been 
clarified; the urine MTs can be used as a biological marker of Cd exposure and Cd-induced renal 
dysfunctions [29,42-44]. In order to characterize the expression and localization of MTs in the rat 
kidneys, here we performed RT-PCR studies in various kidney zones of adult male rats, and 
immunochemical studies in tissue samples using the commercial (anti-MT1/2) and noncommercial 
(anti-MT3) antibodies. A possible expression of MT4 in the rat kidney was not a topic in this study, 
because previous mRNA studies indicated its absence in the mammalian kidneys [7,24].    
 
2. Materials and methods 
2.1.  Animals, and human kidney 
Male Wistar strain rats, 10-12 weeks old, from the breeding colony at the Institute for Medical 
Research and Occupational Health in Zagreb were used. Animals were bred and handled in accordance 
with the Directive 2010/63/EU on the protection of animals used for scientific purposes. Before and 
during experiments, animals had free access to standard laboratory food 4RF21 (Mucedola, Italy) and 
tap water.  
Fresh tissue samples of human kidney cortex were obtained from the local hospitals in Zagreb. The 
samples were obtained from the adult male patiens that underwent surgical operations to remove 
tumors. Informed patient consent was obtained beforehand. The studies in rats and on human tissues 
were approved by the Institutional and hospital Ethic Committees. 
 
2.2. Isolation of RNA, synthesis of first strand cDNA, and end-point RT-PCR 
Rats were sacrificed under general anesthesia (Narketan, 80 mg/kg b.m. + Xylapan, 12 mg/kg 
b.m., i.p.; both from Chassot AG, Bern, Switzerland) by cutting large abdominal blood vessels and 
exsanguination under the stream of cold water. The kidneys were removed, decapsulated, rinsed in ice-
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cold saline, and the middle, ⁓1 mm-thick transversal tissue slice was immediately immersed into 
RNAlater solution (Sigma, St. Louis, MO, USA). The slice was later separated in morphologically 
distinctive zones (cortex, outer stripe, inner stripe, and inner medulla (papilla)) for RNA isolation. 
Total cellular RNA from these tissue zones was extracted using Trizol (Invitrogen, Karlsruhe, 
Germany) and cleaned using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. RNA concentration and its purity was tested spectrophotometrically at 260 
and 280 nm (BioSpec Nano, Shimadzu, Japan). The quality and integrity of RNA was further checked 
by agarose gel electrophoresis, stained with StarGel (Lonza, Rockland Inc., ME, USA), and visualized 
under ultraviolet light. Isolated RNA was stored at -70°C until use. 
First strand cDNA synthesis was performed using the High Capacity cDNA RT Kit (Cat. 
#4374966; Applied Biosystems, Foster City, CA, USA) following the manufacturer’s instructions. 
Total cellular RNA (1 μg) was incubated at 25°C for 10 min in the reaction mixture containing random 
primers and reverse transcribed in total volume of 50 μL containing 1x reverse transcription buffer, 20 
units of ribonuclease inhibitor, 1 mM of dNTP mix, and 40 units of Multiscribe reverse transcriptase, 
by incubation at 37°C for 120 min and final denaturation at 85°C for 10 min. cDNAs were stored at -
20°C until use.. 
RT-PCR was performed in total volume of 20 μL using: 1 μL of 5x diluted first strand cDNA, 0.4 
μM specific primers, and ready to use PCR Master Mix (Applied Biosystems) following instructions 
by the manufacturer. To avoid amplification of genomic DNA, intron over-spanning primers were 
used. Custom primers for the rat genes, rMT1 (subtype MT1a), rMT2 (subtype MT2A), rMT3, and r-
actin were purchased online from Invitrogen (http://bioinfo.ut.ee/primer3-0.4.0/). The primer 
sequences are listed in Table 1. Reaction conditions used for PCR were the following: initial 
denaturation for 3 min at 94°C, denaturation for 30 sec at 95°C, annealing for 30 sec at 57°C and 
elongation for 45 sec at 72°C. The non-template control, where the cDNA was substituted with 
DNase/RNase free water, exhibited no reaction (data not shown). RT-PCR products were resolved by 
electrophoresis in 1.5% agarose gel stained with 1xGelStar (Lonza, Rockland Inc., ME, USA), and 
visualized under ultraviolet light. The housekeeping gene r-actin was used to control variations in the 
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cDNA input. The optimal number of PCR cycles within the exponential phase of the reaction was 20 
for rMT1, 24 for rMT2 and r-actin, and 33 for rMT3. 
2.3. Antibodies and other material 
Commercial monoclonal anti-MT antibody (clone E9; Code M0639, generated against self-
polymerized equine MT1 and MT2), which recognizes a highly conserved domain common to 
mammalian MT1 and MT2 proteins (MT1/2-ab), was purchased from DAKO (Carpinteria, CA, USA). 
This antibody was previously used to study MT1/2 in human organs [24] and in the organs of intact 
and Cd-treated rats [16,45], Noncommercial polyclonal antibody to human MT3/GIF (MT3-ab) was 
previously characterized in immunocytochemical and Western analysis in human organs and cell lines 
[4,5,27,28,41,46]. In this study we also used noncommercial polyclonal antibodies for water channels 
AQP1 (AQP1-ab; it stains the luminal and contraluminal membranes of proximal tubule and thin 
descending limb of Henle (TDLH), and blood capillaries [47]) and AQP2 (AQP2-ab; it stains the 
luminal membrane and intracellular vesicles of the collecting duct principal cells [48]), carboanhydrase 
II (CAII-ab; it stains the cytoplasm and nuclei of various cell types along the nephron with 
heterogeneous intensity [49]), carboanhydrase IV (CA IV-ab; it stains largely the apical membrane of 
S1 and S2 proximal tubule segments and thick ascending limb [50]), megalin (MEG-ab; it stains the 
brush-border membrane (BBM) and subapical endocytic vesiles in proximal tubules [51]), and 
thrombomodulin (TM-ab; it stains the endothelial cells in blood capillaries [52]). We also used the 
noncommercial rabbit-raised polyclonal antibody for 31-kDa subunit of vacuolar ATPase (V-ATPase-
ab; it stains the proximal tubule subapical endosomes and other intracellular vacuoles [51]), 
noncommercial monoclonal antibody for Na+/H+-exchager 3 (NHE3-ab; it stains the proximal tubule 
BBM [51]), and commercial monoclonal antibody for -tubulin (TUB-ab; it stains microtubules) 
[51,53]. FITC-phalloidin (BODIPY FL-Phallacidin, Molecular Probes, Eugene, OR) was used to stain 
actin filaments [53].  
Secondary antibodies were the CY3-labeled donkey anti-mouse (DAMCY3) and goat anti-rabbit 
(GARCY3) IgG, FITC-labeled goat anti-mouse (GAMF) and goat anti-rabbit (GARF) IgG, and 
alkaline phosphatase-labeled goat anti-mouse (GAMAP) or goat anti-rabbit (GARAP) IgG. These 
antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA) 
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or Kirkegaard and Perry (Gaithersburg, MD, USA), and were used in final concentration of 1.6 g/ml 
(GARCY3), 2 g/ml (DAMCY3), 8-10 g/ml (GAMF and GARF), and 0.1 g/ml (GAMAP and 
GARAP). Other chemicals in the study were the highest purity available and were purchased from 
either Sigma (St. Louis, MO, USA) or Fisher Scientific (New Jersey, NJ, USA). 
 
2.4. Tissue fixation and immunocytochemistry 
Under general anesthesia, the kidneys were perfused via the abdominal aorta, first with aerated 
(95% O2/5% CO2) and temperature-equilibrated (37C) phosphate-buffered saline (PBS; in mM: 137 
NaCl, 2.7 KCl, 1.8 KH2PO4, 10 Na2HPO4, pH 7.4) for ~2 min, and then with 50 ml PLP fixative (2% 
paraformaldehyde, 75 mM lysine, 10 mM sodium periodate) [54]. Kidneys were removed, sliced, and 
kept overnight in the same fixative at 4C, followed by extensive washing in PBS, and storage in PBS 
containing 0.02% NaN3 at 4C until further use. Similarly, virtually healthy human kidney tissue was 
separated, rinsed in PBS, and immediately submerged in the fixative, left in it for ~24 h in a 
refrigerator, then extensively washed in PBS, and stored in PBS containing 0.02% NaN3 at 4oC till 
cryosectioning. 
To cut 4 m frozen sections, tissue slices were infiltrated with 30% sucrose (in PBS) overnight, 
embedded in OCT medium (Tissue-Tek, Sakura, Japan), frozen at -25C, and sectioned in a Leica CM 
1850 cryostat (Leica instruments GmbH, Nussloch, Germany). Sections were collected on 
Superfrost/Plus Microscope slides (Fischer Scientific, Pittsburgh, PA; USA) and rehydrated in PBS for 
10 min. Before applying the antibody, cryosections were pretreated for 5 min with 1% sodium dodecyl 
sulfate (1% SDS in PBS) in order to expose cryptic antigenic sites [55]. SDS was removed by 
extensive rinsing in PBS. Nonspecific binding of antibodies was prevented by incubating the sections 
with 1% bovine serum albumin (in PBS) for 15 min before applying primary antibodies. 
In single-staining mode, cryosections were incubated in MT1/2-ab or MT3-ab (diluted in PBS 
1:100) at 4C overnight. This was followed by two washings in high salt PBS (PBS containing 2.7% 
NaCl) in order to decrease the nonspecific binding of antibodies plus two washings in regular PBS (5 
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min each). The sections were then incubated in secondary antibody DAMCY3 or GARCY3 for 60 min, 
and washed in PBS as above. 
In double-staining mode, cryosections were first incubated in MT1/2-ab at room temperature (RT) 
overnight, followed by washings in PBS, then incubated at RT for 3 hours in optimal dilutions of 
polyclonal AQP1-ab, AQP2-ab, TM-ab (each 1:100), MEG-ab (1:1600), or CAII-ab (1:900), washed in 
PBS, then incubated in secondary antibodies DAMCY3 and GARF at RT for 60 min each, and washed 
in PBS. In other double-stainings, cryosections were incubated first in polyclonal V-ATPase-ab 
(1:100), MEG-ab (1:1600), or CAIV-ab (1:1000) at 4C overnight, washed in PBS, incubated in 
monoclonal NHE3-ab (1:100) or TUB-ab (1:50) at RT for 3 hours, washed in PBS, followed by 
incubation in DAMCY3 and GARCY3 at RT for 60 min each, and washed in PBS. Alternatively, 
cryosections were incubated in CAII-ab (1:900) at 4oC overnight, washed in PBS, and then incubated 
in FITC-phalloidin (1:50) at RT for 15 min, and washed in PBS as above. After the last washing, 
cryosections were overlayed a fluorescence fading retardant without or with DAPI (Vectashield; 
Vector Laboratories Inc., Burlingame, CA, USA), coverslipped, and closed with nail polish. 
Where needed, MT1/2-ab was blocked with the commercial equine kidney protein (final 
concentration 0.5 mg/ml; purchased from Sigma, St. Louis, MO, #M4766), whereas MT3-ab was 
blocked with the immunizing peptide (final concentration 0.2 mg/ml) at RT for 4 hours, and then used 
in immunostaining assay as described above. 
The staining was examined with an Opton III RS fluorescence microscope (Opton Feintechnik, 
Oberkochen, Germany) and photographed using a Spot RT Slider camera and software (Diagnostic 
Instruments, Sterling Heights, MI, USA). The images were imported into Adobe Photoshop 6.0 for 
processing and labeling. 
 
2.5. Preparation of tissue homogenates and isolation of  cell cytosol and various organelles 
Rats were sacrificed in deep anaesthesia by cutting abdominal blood vessels and exsanguination 
under the stream of cold water. Kidneys were removed, and tissue zones (cortex, outer stripe, inner 
stripe, inner medulla (papilla)) were dissected manually. The tissues were homogenized for one min in 
a chilled homo-buffer (in mM; 300 mannitol, 5 EGTA, 12 TRIS/HCl, pH 7.4, 1 phenyl-methyl-
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sulfonyl-fluoride (PMSF), 0.1 benzamidine, and 0.1 g/ml antipain) with a Powergen 125 homogenizer 
(Fisher Scientific, New Jersey, NJ, USA). To study MTs, tissue homogenates were centrifuged in a 
refrigerated high speed centrifuge (Sorvall RC-5C; rotor SS34) at 11,000 g for 30 min, the pellet was 
discarded, and the supernatant (denominated as homogenate) was further centrifuged at 19,000 g for 30 
min. The obtained pellet was descarded, whereas the supernatant (denominated as tissue cytosol) was 
used for detection of MTs by immunoblotting. The pieces of fresh human kidney cortex were 
homogenized and processed the same way as described above for the rat tissue. The sample 
denominated as homogenate was used for Western blotting. 
Preparations of BBM, basolateral membranes (BLM), and endocytic vesicles were isolated from 
the rat renal cortical homogenates by the established methods [56,57,58]. In accordance with our 
previous studies performed with the established enzyme activity assays [58,59], in 4 independent 
preparations, isolated BBM were enriched 15.9±1.65-fold and 1.4±0.3-fold in the activity of leucine 
arylamidase (EC 3.4.11.2) and Na+/K+-ATPase (EC 3.6.1.3), respectively. Isolated BLM were enriched 
15.1±1.41-fold and 1.3±0.52-fold in the activity of Na+/K+-ATPase and leucine arylamidase, 
respectively, whereas isolated endocytic vesicles were enriched 38.5±1.72-fold, 2.4±0.17-fold and 
0.52±0.16-fold in the activity of V-ATPase, alkaline phosphatase (EC 3.1.3.1) and Na+/K+-ATPase, 
respectively. 
Nuclei from the rat kidney cortex homogenate were isolated by differential and sucrose density 
gradient centrifugation [60]. The images under phase-contrast indicated no significant contamination of 
isolated nuclei with other organelles. For immunocytochemical investigation, isolated nuclei were 
smeared on the plus slides, fixed with PLP fixative for 30 min, washed in PBS, and further processed 
for immunostaining with MT1/2-ab and MT3-ab, as described above for cryosections. In tissue 
homogenates and isolated organelles, protein was determined by the dye-binding assay [61], and the 
samples were stored at -20C until further use. 
 
2.6. SDS-PAGE and Western blotting 
Before electrophoresis, tissue samples (homogenate, cytosol, isolated membranes, nuclei ) were 
mixed with sample buffer (1% SDS, 12% v/v glycerol, 30 mM Tris/HCl, 5% -mercaptoethanol, pH 
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6.8), and denatured at 95C for 5 min. Proteins (10-50 g protein per lane) were separated through 
20% SDS-PAGE mini gels using the Vertical Gel Electrophoresis System and then electrophoretically 
wet-transferred using Mini Trans-Blot Electrophoretic Transfer Cell (both form Bio-Rad Laboratories, 
Hercules, CA, USA) to Immobilon membrane (Millipore, Bedford, MA, USA). Following transfer, the 
Immobilon membrane was incubated in 1% glutaraldehyde for 60 minutes to enhance MT retention in 
the membrane [62], washed several times with water and blocked in the blotting-buffer (5% nonfat dry 
milk, 0.15 M NaCl, 1% Triton-X-100, 20 mM Tris/HCl, pH 7.4) at RT for 60 min, followed by 
incubation in the same buffer that contained MT1/2-ab or MT3-ab (each 1:500 in PBS) at 4C 
overnight. The membrane was then washed with several changes of blotting-buffer, incubated for 60 
min in the same buffer that contained 0.1 g/ml GAMAP or GARAP, washed again, and stained for 
alkaline phosphatase activity using the BCP/NBT (5-bromo-4chloro-3-indolyl phosphate/nitro blue 
tetrazolium) method to develop the antibody-related bands.  
To test labeling specificity, MT1/2-ab and MT3-ab were blocked with the immunizing proteins 
(final concentration 0.5 mg/ml) at RT for 4 hours prior to the blotting assay. The labeled protein bands 
were evaluated by densitometry. The density of each band was scanned (Ultroscan Laser Densitometer, 
LKB, Bromma, Sweden), and the integrated scan surface was used in further calculations. In 
preliminary experiments we evaluated band densities with different amounts of protein and found that 
these parameters correlated well with up to 50 g protein/lane (data not shown). The integrated surface 
of each scan was expressed in arbitrary units, relative to the surface of the densest band in the control 
samples (=100 arbitrary density units (DU)). In preliminary experiments, the optimal amounts of 
protein/gel lane, which gave linear relationship to the band density, were estimated and used in the 
following studies.  
 
2.7. Transmission electron microscopy (TEM)  
The PLP-fixed kidney cortex tissue was additionally fixed in 2% glutaraldehyde (in PBS) 
overnight and rinsed in PBS. The tissue was postfixed for 1 hour with 1% osmium tetroxid in 
cacodylated buffer. The material was dehydrated through an ethanol concentration series, embedded in 
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Spurr's medium, and ultrathin sections (70–80 nm) were cut with glass knife on an ultramicrotom RMC 
MT6000 XL (Sorvall, USA). The sections were mounted on Formvar-coated grids, stained with 
uranyl-acetat and lead-citrate, and viewed and photographed on transmission electron microscop Zeiss 
EM 10A (Carl Zeiss, Germany).  
 
2.8. Processing of the data 
The immunocytochemical and TEM figures represent findings in 3-4 rats. The images from both 
techniques were imported, assembled, and labeled in PhotoShop. The numeric data, expressed as 
means ± SEM, were evaluated by ANOVA/Duncan at 5% level of significance. 
 
3. Results 
3.1. Expression of MT1, MT2, and MT3 mRNA in tissue zones from male rat kidneys 
As determined by end-point RT-PCR and estimated from the band size, the expression of MT1 
mRNA appeared strongest in the cortex, and much weaker and similar in other tissue zones (Fig. 1). 
The pattern of MT2 mRNA expression was inner medulla>cortex>inner stripe>outer stripe, whereas 
the expression pattern of MT3 mRNA was inner medulla>cortex=outer stripe=inner stripe. The 
localization and distribution of MT proteins along the nephron was further studied by immunochemical 
methods in tissue cryosections and isolated organelles using MT1/2-ab and MT3-ab.  
 
3.2. Distribution of MT1/2 along the rat nephron 
In cryosections of the kidney cortex, the MT1/2-ab-related immunostaining of variable intensity 
was detected in proximal convoluted tubules (Fig. 2A, and inset). The staining was largely 
cytoplasmic, at many places with clear bipolar appearance (inset), being intensive in the apical (large 
arrows) and basal (arrowheads) domains, but some tubule profiles remained partially or completely 
unstained. Some nuclei were also stained (thin arrows). In S3 segments of the outer stripe (Fig. 2B), the 
staining was more heterogeneous, being strong cytoplasmic (large arrows), weak cytoplasmic (large 
arrowheads), or absent (double small arrowheads), while nuclei were either weakly positive (thin 
arrows) or mostly unstained. Thick ascending limbs of Henle loop (TALH) in outer medulla exhibited 
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weak basal staining (Fig. 2C, arrows). However, some tubule profiles in the proximal region of inner 
medulla contained cells that were strongly stained in both cytoplasm and nuclei (Fig. 2D, arrows). In 4 
rats, the immunoreactivity in this region was always present, however with heterogeneous intensity, 
from strong (Fig. 2D) to weak (not shown). More distal nephron parts, in the inner medulla (papilla) 
remained unstained (not shown). 
In order to define the MT1/2-positive nephron segment in inner medulla, shown in Fig. 2D, 
cryosections of this region were double stained with MT1/2-ab and with antibodies for marker proteins 
known to be localized in the specific kidney structures. As shown in Fig. 3, the MT1/2-related staining 
did not colocalize with AQP1 in thin descending limbs and capillaries (A), with AQP2 in collecting 
ducts (B), and with thrombomodulin in capillaries (C). Therefore, we conclude that the nephron 
segment positive for MT1/2 was the thin ascending limb of Henle loop (thin ALH). 
In order to further confirm the zonal-dependent abundance of MT1/2 protein, we performed 
Western blot analysis of the tissue homogenates (Fig. 4A and B) and isolated organelles (Fig. 4C). As 
shown in Fig. 4A, the broad MT1/2-ab-related  protein band of 6-8 kDa was strongest in the cortex and 
weak in other tissue zones, in inner medulla being a slightly stronger than in the outer and inner stripe. 
The densitometric evaluation of these bands (Fig. 4B) confirmed the immunocytochemical pattern 
shown in Fig. 2. Furthermore, to test if the observed bipolar distribution of MT1/2-ab-related staining 
in the cortical proximal tubules, shown in Fig. 2A, was confined with specific cell organelles, the 
abundance of MT1/2 protein was tested by immunoblotting the tissue cytosol (TC) and isolated BBM, 
BLM, and endocytic vesicles (EV). As shown in Fig. 4C, the respective protein band was abundant in 
the tissue cytosol, but largely absent in isolated membrane organelles. A faint band of 7-8 kDa in 
isolated BBM may reflect a small content of MT1/2 protein encapsulated in membrane vesicles during 
homogenization.  
 
3.3. MT1/2-rich organelles in the tubule lumen 
In addition to intracellular staining, in the lumen of some cortical proximal tubule profiles we 
observed largely spheroid, droplet-like formations, brightly-stained with MT1/2-ab (Fig. 5A and B, 
arrows). These formations had various sizes (and, sometimes, different shapes), generally smaller than 
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the size of nucleus (<5 m in diameter), and many of them were attached to the tubule BBM surface 
(Fig. 5B, arrow). The number of these formations per cryosection varied in different rats, from zero to 
a few, and their frequency in the female tubules was smaller than in males (not shown). This sex-
related phenomenon was not further studied. 
Serial images, double stained with MT1/2-ab and MEG-ab indicated that these luminal, MT1/2-
rich formations may be generated by a developing process, which starts with budding of a small 
compartment from the apical cell domain and finishes with the final detachment (Fig. 5C-F, 
arrowheads). The cells that exhibited budding of MT1/2-rich droplets were usually stained strongly 
with MT1/2-ab, and had normal (non-fragmented) nucleus (Fig. 5G, arrows; as also indicated by the 
intact nuclei in TEM images (c.f. Fig. 7A)), excluding apoptosis as being involved. In the lumen of S3 
segments, the usual MT1/2-rich formations were rare (Fig. 5H, arrowheads), mostly only the MT1/2-
positive fragmented material was observed (Fig. 5H, arrows).  
Double staining of these luminal formations with MT1/2-ab and several antibodies to cytoplasmic 
or membrane-bound antigens (Fig. 6A-G2) indicated that the MT1/2-rich formations are vesicles, 
surrounded by the NHE3-positive membrane (D1 and D2, arrows), which are strongly positive for CA 
II (A-C, arrows), but negative for V-ATPase (E1 and E2, arrows), actin (F1 and F2, arrows), tubulin 
(G1 and G2, arrows), and CA IV (not shown). 
Budding of vesicles from the luminal cell domain in cortical proximal tubules, as a possible source 
of MT1/2-rich luminal vesicles was further indicated by TEM, where different stages of vesicle 
formation at the luminal cell surface can be observed (Fig. 7). 
 
3.4. Distribution of MT3 along the rat nephron 
The rabbit-raised antibody for C-terminal peptide of human MT3 was first tested for its staining 
efficiency in cryosections of the human kidney cortex, and by immunoblotting of the human kidney 
cortex homogenate (Fig. 8). As shown in Fig. 8A, MT3-ab stained with heterogeneous intensity the cell 
cytoplasm of proximal and distal tubules, and cortical collecting ducts. The staining was absent with 
the immunizing peptide-blocked MT3-ab (Fig. 8B). In Western blot of the cortex homogenate (Fig. 
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8C), MT3-ab labeled strongly the expected protein band of 7-8 kDa, and weakly a few upper bands (-
P), all being absent with the peptide-blocked antibody (+P). 
Immunoreactivity of MT3-ab in various tissue zones of the rat kidney is shown in Fig. 9. In 
various tubule profiles in the cortex (A and B), outer stripe (D), inner stripe (F), and inner medulla (H), 
the antibody stained the cell cytoplasm with heterogeneous, largely weak intensity, whereas nuclei in 
all renal structures were stronger stained (arrows). In some cortical proximal tubule profiles, a limited 
staining of BBM was also observed (A and B, arrowheads). The staining in all renal structures was 
absent with the peptide-blocked MT3-ab (C, E, G, I). 
 
3.5. MTs in isolated renal nuclei 
In order to test the presence of MT1/2 and MT3 in renal nuclei, nuclei from the rat kidney cortex 
were isolated by the established method, and probed by immunochemical methods with MT1/2-ab and 
MT3-ab (Fig. 10). Under phase contrast, the preparation of isolated nuclei appeared fairly devoid of 
other cellular structures as contaminats (Fig. 10A). By immunostaining, nuclei remained unstained 
with MT1/2-ab (Fig. 10B). On the contrary, the staining with MT3-ab was bright (Fig. 10C, and inset) 
and absent with the immunizing peptide-blocked antibody (Fig. 10D). In accordance with 
immunocytochemical data, in Western blots the isolated nuclei exhibited no MT1/2-ab-related protein 
band (Fig. 10E, N), whereas MT3-ab labeled the 7-8 kDa protein band (Fig. 10F, -Pept, N, arrow) and 
a few uper bands, all being absent or strongly diminished with the immunizing peptide-blocked 
antibody (Fig. 10F, +Pept, N).  
 
 
4. Discussion 
Using the methods of end-point RT-PCR in total cell RNA, indirect immunofluorescence 
cytochemistry in tissue cryosections, and Western blotting of variuos tissue samples, here we report on 
the expression and detailed immunolocalization of MT1/2 and MT3 in the kidneys of adult male rats. 
The RT-PCR data showed the presence of MT1, MT2, and MT3 mRNA in all four tissue zones with 
heterogeneous expression; the expression of MT1 mRNA was highest in the cortex, whereas the 
expression of MT2 mRNA and MT3 mRNA was highest in the inner stripe. 
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Immunolocalization of MT proteins was performed with commercial monoclonal MT1/2-ab and 
noncommercial polyclonal MT3-ab. Although the MT1/2-ab does not discriminate between MT1 and 
MT2 proteins, the pattern of mRNA expression indicates that the MT1 protein may be most abundant 
protein in the cortex, the MT2 protein may be most abundant in the inner medulla, whereas the MT3 
protein may be distributed evenly in the cortex, outer stripe and inner stripe, and more abundant in the 
inner medulla. Heterogeneous, largely cytoplasmic but also nuclear immunoreactivity with MT1/2-ab 
was observed in several nephron segments, whereas in ascending thin limb, a weak immunoreactivity 
was exclusively cytoplasmic and located in the basal cell domain. Heterogeneity in the cytoplasmic 
content of MTs may be related to different, segment-specific metabolic rates that produce oxidative 
radicals, or to different exposure to toxic metals which are filtered via glomeruli, reabsorbed from the 
tubule lumen, and then acted by inducing synthesis of MTs [16]. Furthermore, being small molecules, 
MTs can be released from liver and other organs, filtered in glomeruli, and reabsorbed in proximal 
tubule by endocytosis [16]. However, the isolated renal cortical endocytic vesicles did not exhibit a 
visible protein band of MT1/2, indicating that in physiological conditions, filtration and endocytosis of 
the filtered MTs in male rats may be low, under detection limits. This phenomenon dramatically 
changes following treatment of rats with Cd or some other toxic metal, when the expression of MTs is 
strongly upregulated in hepatocytes and renal tubules, and MTs are released from both damaged 
hepatocytes and tubule cells  [16], a condition also manifested with a detectable excretion of MT1/2 in 
urine [63]. 
In this study, the cytoplasmic MT1/2-ab-related staining in most cortical proximal tubules (S1/S2 
segments) was distributed in two poles, stronger in the luminal and weaker in the contraluminal 
domain. In the outer stripe (S3 segments), however, the cytoplasmic staining was much weaker and 
homogeneous, without bipolar distribution. A predominant localization of MT1/2 staining in the 
luminal domain was previously reported in proximal tubules of the adult rat [38] and human kidneys 
[18], whereas in the study in human kidneys by Mididoddi et al. [24], the MT1/2 immunoreactivity was 
uniformly present in the proximal tubule cell cytoplasm. However, in this study we could not 
demonstrate a significant protein band of MT1/2 proteins in isolated luminal (BBM) and contraluminal 
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(BLM) membranes, indicating that the cytoplasmic proteins were not firmly associated with these 
membrane domains.  
The cells with strongest abundance of MT1/2 immunoreactivity in the luminal domain seem to 
release a part of this cargo in form of vesicles, which were formed by exvagination of the BBM. The 
finding of MT1/2-positive material in the proximal tubule lumen of animal and human kidneys was 
previously described [21,34,35,38], but this phenomenon has not been further investigated. The 
fixation and staining techiques in our (PLP fixation in vivo and the indirect immunofluorescence 
staining in frozen tissue sections) and previous studies (Bouin’s fixative or 10% buffered formalin by 
immersion and staining by immunoperoxidase method in paraffin sections) were different, thus 
indicating that the MT1/2-positive material in the tubule lumen was not related to the fixation and 
staining methods. Our studies with a single and double staining confirmed these findings as the MT1/2-
positive vesicles in the lumen of cortical proximal tubules (S1/S2 segments), and further revealed that: 
a) MT1/2-rich vesicles seem to be formed by exvagination of the apical cell membrane (BBM) in the 
cells that are strongly stained for MT1/2 in their apical domain, in which various stages of the vesicle 
formation can be observed, b) the size of the MT1/2-rich vesicles is heterogeneous, 1-5 m in 
diameter, and c) their limiting membrane was positive for the BBM marker NHE3, but not for megalin, 
V-ATPase and CA IV, whereas the intravesicular cargo contained the cytoplasmic MT1/2 and CA II, 
but not the cytoskeletal proteins actin and tubulin. However, we can not exclude the possibility that the 
vesicels contained all these proteins in very small concentrations, which were under the detection limits 
of our method. 
The driving force for vesiculation of these MT1/2-rich formations and their detachment from the 
BBM is not clear. It may represent a process of continuous change in plasticity of the proximal tubule 
cells, where parts of BBM are removed by exvagination (shedding) in form of vesicles into the tubule 
lumen (a posibility shown also by TEM), and then replenished by newly synthetized membrane 
components via the intracellular vesicle trafficking. The observation that such vesicles are generated 
predominantly in the cells with very high subapical content of MT1/2 indicates that the apical 
accumulation of MTs in these cells may not be accidental, and may have some functional role in 
formation and detachment of the vesicles into the tubule lumen. The cells exhibiting formation of such 
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vesicles have intact nucleus, indicating that the observed vesiculation is not a part of apoptotic process. 
Rather, this phenomenon may be a physiologically-relevant secretory process to remove over-
accumulated nontoxic and/or toxic cytoplasmic content in a bulk form. 
The MT1/2-rich vesicles were relatively frequent in the lumen of proximal tubule S1/S2 segments 
in the cortex, rare and often fragmented in the lumen of proximal tubule S3 segments in the outer 
stripe, and absent in nephron segments located in more distal segments. The fragmented vesicles and 
liberated MTs may finish in urine, thus representing the source of MT1/2 in urine of intact, and much 
more in Cd-intoxicated animals and humans [42-44]. As suggested previously [16], the liberated 
MT1/2 in the tubule lumen may have a protective role by neutralizing ROS and RNS, and by binding 
toxic metals that may reach the tubule fluid by glomerular filtration or be released from the tubule 
cells. Also, these vesicles may be the source of various molecules for cell-to-cell communication 
(reviewed in [64]), CA II and other proteins (previously attributed to the glomerular filtration and 
“leakage” of the protein from the proximal and distal tubules [65]), and microvesicles and other 
membranous material in the urine of healthy people and of patients with kidney diseses [66]. 
As shown here, the cells in thin ascending limb of Henle represent another place of a significant 
immunoreactivity with MT1/2-ab, stronger in the nuclei than in the cytoplasm. The mRNA expression 
data in Fig. 1 suggest that the predominant MT isoform in this nephron segment may be MT2. Since 
the real function of individual MTs in mammalian cells is not known, a possible physiological rationale 
for predominant localization of MT2 in this part of the nephron remains to be determined in future 
studies. 
Besides in the cytoplasm, a number of nuclei in the cells of proximal tubule S1, S2 and S3 
segments also exhibited heterogeneous staining with MT1/2-ab. Similar heterogeneity in nuclear 
localization of MT1/2 was previously observed in the rat [19] and human [21,24] proximal tubules. 
However, the isolated nuclei from the renal cortex showed neither immunostaining nor protein band 
with MT1/2-ab, indicating that the MT1 and/or MT2 proteins were not firmly attached to the nuclear 
structures and were lost during isolation procedure. As reviewed before [16], the nuclear MT1/2 may 
originate from cytosol, but the exact mechanism of its translocation from the cytosol into the nucleus 
(and opposite) is not clear. The molecule is enough small to pass through the nuclear pores, but 
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possible triggers for this translocation and nuclear retention are unclear [67,68]. The nuclear MTs may 
deliver Zn and/or Cu needed for normal function of RNA, various metalloproteins (metalloenzymes, 
Zn-finger proteins), and growth and transcription factors that regulate the activity of various genes and 
protect the cell from ROS- and RNS-mediated DNA damage and apoptosis [69,70]. The high levels of 
MTs in nuclei indicate an increased need for Zn in metalloenzymes and transcription factors during 
rapid cell growth. Thus, the elevated nuclear presence of MTs in fetal period, in some cancers, and 
during liver regeneration after partial hepatectomy, indicates proliferative activity of the cells 
[25,71,72]. 
In contrast to MT1 and MT2 mRNA expression, the expression of MT3 mRNA was relatively 
uniform in tissue zones, but slightly higher in inner medulla (papilla). Previous studies revealed a very 
heterogeneous expression of MT3 mRNA and protein in various rat organs, highest in the brain, but 
very low in the heart, liver and kidneys. By immunocytochemistry in paraffin sections of the male rat 
kidneys, MT3 protein was previously detected in the cytoplasm of glomerular and collecting duct cells 
[6]. In human kidneys, the protein was demonstrated only in the cell cytoplasm of proximal and distal 
tubules, and collecting ducts [4]. These localizations are confirmed in the present immunocytochemical 
study in cryosections of the human kidney cortex. A number of previous studies showed that, different 
from MT1/2, whose expression was strongly upregulated by various inducers including Cd and Zn [16, 
and refrences in there], the MT3 mRNA and protein expression was only transiently and weakly 
induced by these metals [3,73]. The studies in cultured human proximal tubule (HK-2) cells showed 
that the isoform MT3 may be involved in water and ion transport, contributing to domes formation [5], 
and may increase sensitivity of the cells to Cd-induced cytotoxicity, driving the mechanism of cell 
death from apoptosis to necrosis, possibly via activating early response genes c-fos, c-jun and c-myc 
[27,28,73]. The MT3-knockout mice were resistant to Cd-induced hepatotoxicity [15], thus indicating 
that this poory defined MT3-mediated mechanism of cytotoxicity operates also in vivo in some 
mammalian organs. In human brain cells, however, MT3 exhibited different roles; it showed 
neuroprotective function following traumatic or hypoxic brain damage, in cultured neurons 
acted as a growth inhibitory factor (GIF), while downregulation of its expression and loss of its 
protective and/or repair functions due to diminished cellular capacity to neutralize ROS may be 
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associated with Alzheimer's and other neurodegenerative diseases [31,74]. Furthermore, 
overexpression of MT3 mRNA and/or related cytoplasmic protein was detected in many cases of 
human breast, bladder and prostatic cancers [75, and references in there].  
As shown in the present study, the MT3-ab only weakly stained the cell cytoplasm of cortical 
proximal convoluted tubules, distal tubules and collecting ducts, and of S3 segments in the outer stripe. 
In some cortical proximal tubules, a weak staining of the luminal membrane was also observed. 
However, nuclei were heterogeneously stained in the cells of all nephron segments. The staning of 
granular appearance, and the respective protein band of 7-8 kDa in Western blot were retained in 
isolated cortical nuclei, indicating a firm association of MT3 with the unknown nuclear structures. The 
role of predominantly nuclear localization of MT3 protein in renal cells can be speculated in view of 
the known properties and functions of this and other metallothionenins. MT3 protein may primarily 
regulate intracellular concentration of Zn, where it exhibits some properties different from other MTs: 
a) it binds Zn ions more weakly, and exhibits higher metal-binding capacity than, for example, 
MT2, and b) binding to, and release of Zn from the molecule is a highly sensitive to redox 
state, which is related to production of ROS in oxidative stres [29,76, and references in there]. 
With these characteristics, MT3 may bring resistance to Zn toxicity in case of overloading, 
protect cells from ROS generated during normal and intense metabolism, and control Zn 
concentration in the cytoplasm and nuclei, necessary for optimal function of Zn-finger and 
other metalloproteins (enzymes, growth and transcription factors), which regulate activity of 
the genes, RNAs, and other cellular functions [69,70,76]. However, since MT3 Zn-binding sites 
are highly redox-sensitive, the protein can bind or release Zn in response to changes in 
oxidative status, and may even accelerate cell death due to cytotoxicity in acute oxidative 
injury caused by hyperproduction of ROS. In this condition, MT3 and other Zn-binding 
proteins release Zn ions which contribute to lysosomal membrane permeabilization and liberation of 
various catabolic enzymes, causing degradation of cellular content, cell necrosis and dead. On the other 
side, when cells are exposed to reducing conditions the apo-form of MT3 may bind more Zn. 
[76. and references in there]. 
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5.  Conclusion  
Metallothioneins MT1, MT2, and MT3 are heterogeneously expressed in the cell cytoplasm and/or 
nuclei along the rat nephron. Some proximal tubule cells in the cortex exhibit very high abundance of 
MT1/2 in their apical domain. These cells may generate and release small, MT1/2-rich vesicles, which 
are detached from the luminal cell membrane and found in the tubule lumen. The vesicles may be 
formed by continuous change of the cell plasticity, which may be driven by intracellular MT1/2 by 
unknown mechanism, and may represent the source of urine MTs and vesicular material. In the tubule 
fluid, the intravesicular MT1/2 my protect the luminal membrane of tubular cells from the damaging 
effects of  ROS- and/or NOS which may be filtered and/or released from the nephron cells. The MT3-
related immunostaining was weak in the cell cytoplasm of various cortical tubules, and stronger in 
nuclei of all nephron segments. In these compartments, MT3 may regulate local concentration of Zn 
ions necessary for the function of various Zn-dependent proteins (enzymes, growth and transcription 
factors, Zn-finger proteins) that modulate the activity of genes, RNAs, and other cellular functions. 
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Table 1. Primer sequences used in end-point RT-PCR studies of rat metallothionein genes 
 
Gene 
Forward (F)/Reverse (R) 
Primers (5’-3’) 
Accession No. 
Gene Bank 
Location RT-PCR 
product (bp) 
rMT1a F: CACCAGATCTCGGAATGGAC 
R: CAGCAGCACTGTTCGTCACT 
NM_138826.4 56-75 
275-256 
220 
rMT2A F: CACAGATGGATCCTGCTCCT 
R: AAGTGTGGAGAACCGGTCAG 
NM_001137564.1 86-105 
334-315 
249 
rMT3 F: CCTGGATATGGACCCTGAGA 
R: AGGGACACGCAGCACTATTC 
NM_053968.2 60-80 
308-288 
249 
r-Actin F: GTCGTACCACTGGCATTGTG 
R: AGGAAGGAAGGCTGGAAGAG 
NM_031144.2 518-537 
862-881 
364 
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10. Figure legends 
 
Fig. 1. Expression of MTs mRNA as determined by end-point RT-PCR in kidney tissue zones of an 
adult male rat. A housekeeping gene -actin is similarly expressed in all tissue zones. The data are 
representative for similar findings in 3 rats. CO, cortex; OS, outer stripe; IS, inner stripe; IM, inner 
medulla (papilla. 
 
Fig. 2. Immunolocalization of MT1/2 along the nephron of an adult male rat. A. Cortex (and inset). In 
proximal convoluted tubules, the MT1/2-ab-related immunostaining was heterogeneous in intensity, 
and in many places with bipolar appearance, being concentrated in subapical (thick arrows) and basal 
(arrowheads) domains of the tubule epithelium. Some nuclei were aslo clearly stained (thin arrows). 
Glomeruli and other nephron segments in the cortex remained unstained (not shown). B. Outer stripe. 
Heterogeneous staining in the cells of S3 segments; the staining was strong (thick arrows) or weak 
(large arrowheads) cytoplasmic, or absent (small double arrowheads). Most nuclei were unstained, but 
some nuclei were clearly stained  (thin arrows). C. Inner stripe. Thick ascending limbs of Henle 
exhibited weak staining at the basal domain (arrows). D. Inner medulla. Thin tubule profiles in the 
proximal region of inner medulla contained cells that expressed high levels of the staining in both 
cytoplasm and nuclei (arrows). More distal nephron parts in the inner medulla (papilla) remained 
unstained (not shown). Bar, 20 m. 
 
Fig. 3. Characterization of MT1/2-positive nephron segment in inner medulla; double staining using 
antibodies for specific marker proteins. A. Staining with MT1/2-ab (red fluorescence, arrowheads) and 
AQP1-ab (green fluorescence) did not colocalize; AQP1 was localized in the plasma membrane of 
descending thin limb of Henle (large arrows) and blood capillaries (thin double arrows). B. Staining 
with MT1/2-ab (red fluorescence, large arrowheads) and AQP2-ab (green fluorescence, large arrows) 
did not colocalize; AQP2 was localized in the principal cells of inner medullary collecting duct. Dark 
cells in the collecting ducts remained unstained with both antibodies (thin double arrows). C. Staining 
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with MT1/2-ab (red fluorescence, arrowheads) and TM-ab (green fluorescence) did not colocalize; 
thrombomodulin was localized in blood capillaries (arrows). Bar (for all images), 20 m. 
  
Fig. 4. Western blot of MT1/2 in tissue cytosol and isolated organelles from various zones of the rat 
kidney. A. The abundance of MT1/2 in tissue cytosol from the kidney cortex (CO), outer stripe (OS), 
inner stripe (IS), and inner medulla (IM) of male rats. Each protein band represents a tissue sample (50 
g protein/lane) from separate animal. B. Densitometric evaluation of the bands shown in A. Each bar 
is the mean ± SEM of the data in tissue cytosols from 3-4 rats. Statistics (ANOVA): a vs. b, c or d, P < 
0.001; c vs. d, P < 0.05. Other relations, not significant. DU = arbitrary density units. C. Abundance of 
MT1/2 in tissue cytosol (TC) and in brush-border membranes (BBM), basolateral membranes (BLM), 
and endocytic vesicles (EV) isolated from the kidney cortex. Each band represents protein sample (50 
g protein/lane) from separate animal.   
 
Fig. 5. Immunolocalization of MT1/2-rich spherical formations (organelles) in the lumen of proximal 
tubules. A-B, MT1/2-rich formations in the lumen of some cortical proximal tubules (arows). C-F, 
Serial images indicating formation, budding, and detachment of MT1/2-rich organelle (arrowheads) via 
an apical process from the MT1/2-rich epithelial cells. Double staining with MT1/2-ab (red 
fluorescence) and MEG-ab (green fluorescence). The final, detached organelles (F, arrowheads) were 
strongly positive for MT1/2 and negative for MEG.  G. Double staining of proximal tubule with 
MT1/2-ab (red fluorescence) and nuclei with DAPI (blue fluorescence). The cells that form and shed 
MT1/2-rich organells (arrowheads) had normally-shaped nuclei (arrows). H. Double staining with 
MT1/2-ab (red fluorescence) and MEG-ab (green fluorescence) in cryosections of outer stripe. In the 
lumen of S3 segments, the compact MT1/2-rich organelles were rare (arrowheads) and largely 
fragmented (arrows). In more distal parts of the nephron, these organelles were not observed (not 
shown). Bars, 20 m. 
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Fig. 6. Immunocytochemical characterization of MT1/2-rich organelles in the proximal tubule lumen; 
double staining with using antibodies for specific proteins. A-C, Immunostaining with MT1/2-ab (A, 
red staining, arrows), CA2-ab (B, green staining, arrows), and merged image (C, arrows) showed a 
complete colocalization, giving brightly yellow-stained organelles. D1-D2, CA2-positive organelle 
(D1, green staining, arrow) was surrounded with the NHE3-ab-positive membrane (D2, red staining, 
arrow), proving the MT1/2-rich formation being a vesicle. NHE3-ab also stained strongly the tubule 
BBM (D2, arrowhead). The general intensity of red fluorescence was enhanced in PhotoShop in order 
to reveal weak staining of the vesicle limiting membrane. E1-E2, The MT1/2-rich vesicle (E1, green 
stained, arrow) was co-stained with V-ATPase-ab (E2, red fluorescence, arrow). V-ATPase-ab stained 
subapical endocytic vesicles (E2, arrowhead) and intracellular vacuoles (mainly lysosomes), but not the 
MT1/2-rich vesicle (E2, arrow). F1-F2, MT1/2-rich vesicle (F1, red staining, arrow) was co-stained 
with FITC-phalloidin, a marker for actin in BBM (F2, green, arrowhead). The MT1/2-rich vesicle was 
negative for actin (F2, arrow). G1-G2, the CA2-positive vesicle in the tubule lumen (G1, green 
staining, arrow) was not stained with TUB-ab (G2, arrow), wich stained microtubules in the tubule 
epithelial cells (G2, red staining, arrowhead). Similarly, the MT1/2-rich vesicles were not stained with 
CA4-ab (data not shown). Bar, 20 m for all images. 
 
Fig. 7. Transmission electron microscopy of the cortical proximal tubule from the adult male rat 
kidney; possible source of putative MT1/2-rich organelles in the tubule lumen. Shown are various 
stages of formation by budding and shedding of membrane vesicles (asterisks) that may contain MT1/2 
and other cytoplasmic molecules. A, The would-be vesicle with a wide connection to the cell surface. 
B, The vesicle with a thin connection to the cell surface. C, Fully detached vesicle. D, Free, round-
shape vesicles of heterogeneous size in the tubule lumen. The limiting vesicle membrane is indicated 
by strong contrast (arrowheads). BB, brush border microvilli. N, nucleus. Bars, 1.5 m. 
 
Fig. 8.  Immunoreactivity of MT3-ab in the human kidney cortex tissue. A, The cell cytoplasm of 
proximal (PT) and distal (asterisk) tubules, and of cortical collecting duct (CD) were stained with 
heterogeneous intensity. The cells in glomerulus (G) and nuclei in the tubule epithelium remained 
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unstained. B, Absence of staining with the immunizing peptide-blocked MT3-ab. C, Western blot of 
the cortex homogenate with MT3-ab. Labeled was strongly the protein band of 7-8 kDa, and weakly a 
few upper bands, probably reflecting polymerized proteins (-P). All the bands were abolished with the 
immunizing peptide-blocked antibody (+P). 
 
Fig. 9. Immunoreactivity of MT3-ab in various kidney zones of the adult male rat (A, B, D, F, H)  and 
its absence with the immunizing peptide-blocked antibody (C, E, G, I). In the cells of glomeruli and 
various tubule profiles in the cortex (A and B), outer stripe (D), inner stripe (F), and inner medulla (H), 
cytoplasm was heterogeneously but weakly stained, whereas nuclei in all renal structures were stronger 
stained (arrows). Some cortical proximal tubules also exhibited variable staining of the luminal 
membrane (A and B, arrowheads). The staining in all structures was absent with the peptide-blocked 
MT3-ab (C, E, G, I). G, glomeruli; S1 and S3, proximal tubule S1 and S3 segments; DT, distal tubule; 
CD, collecting duct; TALH, thick ascending limb of Henle loop. Bar, 20 m for all images. 
 
Fig. 10. MT1/2 and MT3 in isolated nuclei; immunocytochemical (A-D) and Western blot studies (E 
and F). A (and inset), Dark field image of nuclei isolated from the kidney cortex. B, Absence of 
immunoreactivity with MT1/2 antibody in isolated nuclei. C (and inset), strong immunoreactivity with 
MT3-ab in isolated nuclei. D, Absence of immunoreactivity with the peptide-blocked MT3-ab. Bar, 20 
m for all immages. E, Western blot of the renal cortical homogenate (HOM) and isolated nuclei (N) 
with MT1/2-ab. F, Western blot of the renal cortical homogenate (HOM) and isolated nuclei (N) with 
MT3-ab (-Pept) and with the peptide-blocked MT3-ab (+Pept). 7-8 kDa protein band, labeled with 
MT3-ab is indicated with an arrow. Each lane contained 50 g protein. 
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